252 related articles for article (PubMed ID: 33462615)
1. Paraneoplastic Secretion of Multiple Phosphatonins From a Deep Fibrous Histiocytoma Causing Oncogenic Osteomalacia.
Leow MKS; Dogra S; Ge X; Chuah KL; Liew H; Loke KSH; McFarlane C
J Clin Endocrinol Metab; 2021 Apr; 106(5):e2299-e2308. PubMed ID: 33462615
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic osteomalacia, a rare paraneoplastic syndrome due to phosphate wasting--a case report and review of the literature.
Woznowski M; Quack I; Stegbauer J; Büchner N; Rump LC; Schieren G
Clin Nephrol; 2008 Nov; 70(5):431-8. PubMed ID: 19000546
[TBL] [Abstract][Full Text] [Related]
3. [Tumor-associated hypophosphatemic osteomalacia: case report and literature review].
Ewerbeck V; Simank HG; Krempien B
Z Orthop Ihre Grenzgeb; 1994; 132(6):491-6. PubMed ID: 7831951
[TBL] [Abstract][Full Text] [Related]
4. Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia.
Habra MA; Jimenez C; Huang SC; Cote GJ; Murphy WA; Gagel RF; Hoff AO
Endocr Pract; 2008 Dec; 14(9):1108-14. PubMed ID: 19158050
[TBL] [Abstract][Full Text] [Related]
5. [Tumor localization and treatment of tumor-induced osteomalacia].
Beil FT; Stürznickel J; Rolvien T; Amling M; Oheim R
Z Rheumatol; 2022 Apr; 81(3):182-188. PubMed ID: 35103802
[TBL] [Abstract][Full Text] [Related]
6. [Oncogenic osteomalacia: the role of the phosphatonins. Diagnostic usefulness of the Fibroblast Growth Factor 23 measurement in one patient].
Dupond JL; Magy N; Mahammedi M; Prie D; Gil H; Meaux-Ruault N; Kantelip B
Rev Med Interne; 2005 Mar; 26(3):238-41. PubMed ID: 15777586
[TBL] [Abstract][Full Text] [Related]
7. Bilateral insufficiency fracture of the femoral head and neck in a case of oncogenic osteomalacia.
Chouhan V; Agrawal K; Vinothkumar TK; Mathesul A
J Bone Joint Surg Br; 2010 Jul; 92(7):1028-31. PubMed ID: 20595128
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma.
Leaf DE; Pereira RC; Bazari H; Jüppner H
J Clin Endocrinol Metab; 2013 Mar; 98(3):887-91. PubMed ID: 23393166
[TBL] [Abstract][Full Text] [Related]
9. Clinical and bone density outcomes of tumor-induced osteomalacia after treatment.
Umphrey LG; Whitaker MD; Bosch EP; Cook CB
Endocr Pract; 2007 Sep; 13(5):458-62. PubMed ID: 17872346
[TBL] [Abstract][Full Text] [Related]
10. [Hypophosphatemic osteomalacia secondary to a vascular fibrous histiocytoma].
Insua Vilariño SA; Díaz Garel J; Caamaño Freire M; Mera Varela A; Buelta Carrillo L; Pérez Becerra E; Varela Durán J
Rev Clin Esp; 1993 Oct; 193(6):293-5. PubMed ID: 8259452
[TBL] [Abstract][Full Text] [Related]
11. Dual paraneoplastic syndromes: small cell lung carcinoma-related oncogenic osteomalacia, and syndrome of inappropriate antidiuretic hormone secretion: report of a case and review of the literature.
Tantisattamo E; Ng RC
Hawaii Med J; 2011 Jul; 70(7):139-43. PubMed ID: 21886301
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic hypophosphatemic osteomalacia.
Agus ZS
Kidney Int; 1983 Jul; 24(1):113-23. PubMed ID: 6312153
[No Abstract] [Full Text] [Related]
13. Occult phosphaturic mesenchymal tumour of femur cortex causing oncogenic osteomalacia - diagnostic challenges and clinical outcomes.
Dutta D; Pandey RK; Gogoi R; Solanki N; Madan R; Mondal A; Dogra S; Thapa P
Endokrynol Pol; 2018; 69(2):205-210. PubMed ID: 29442350
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic osteomalacia: two case reports with surprisingly different outcomes.
Seijas R; Ares O; Sierra J; Pérez-Dominguez M
Arch Orthop Trauma Surg; 2009 Apr; 129(4):533-9. PubMed ID: 19125258
[TBL] [Abstract][Full Text] [Related]
15. Clinical Characteristics of Malignant Phosphaturic Mesenchymal Tumor Causing Tumor-Induced Osteomalacia.
Abate V; Vergatti A; De Filippo G; Damiano V; Menale C; D'Elia L; Rendina D
J Clin Endocrinol Metab; 2024 Feb; 109(3):e1006-e1011. PubMed ID: 38006315
[TBL] [Abstract][Full Text] [Related]
16. Persistent tumor-induced osteomalacia confirmed by elevated postoperative levels of serum fibroblast growth factor-23 and 5-year follow-up of bone density changes.
Zimering MB; Caldarella FA; White KE; Econs MJ
Endocr Pract; 2005; 11(2):108-14. PubMed ID: 15901526
[TBL] [Abstract][Full Text] [Related]
17. [Detection of the primary tumor site in tumor-induced osteomalacia by indium-111 octreotide scintigraphy: a case report].
Takahashi M; Toru S; Ota K; Izumiyama H; Yokota T; Mizusawa H
Rinsho Shinkeigaku; 2008 Feb; 48(2):120-4. PubMed ID: 18326305
[TBL] [Abstract][Full Text] [Related]
18. Tumor-induced osteomalacia - a mystery illness beyond aches, pains, and depression.
Ni HJ; Clifton-Bligh R; Brzozowska MM
Endocr Regul; 2021 Sep; 55(3):163-168. PubMed ID: 34523297
[No Abstract] [Full Text] [Related]
19. Clinical, morphological and immunohistochemical analysis of 13 cases of phosphaturic mesenchymal tumor - A holistic diagnostic approach.
Chatterjee D; Bardia A; Pal R; Saikia UN; Bhadada SK; Radotra BD
Ann Diagn Pathol; 2021 Oct; 54():151783. PubMed ID: 34329884
[TBL] [Abstract][Full Text] [Related]
20. Osteomalacia induced by a phosphaturic mesenchymal tumor secreting fibroblast growth factor 23.
Nagae K; Uchi H; Ito T; Moroi Y; Oda Y; Furue M
Eur J Dermatol; 2015 Apr; 25(2):199-200. PubMed ID: 25788099
[No Abstract] [Full Text] [Related]
[Next] [New Search]
